(NYSE:IQV) today announced the launch of IQVIA MedTech and its dedicated
industry focused solutions and services for the medical device and in
vitro diagnostics market, and for companies with combination products.
IQVIA MedTech empowers companies to orchestrate operations across their
entire product lifecycle, from concept-to-market, providing quality
control, regulatory, safety and compliance solutions along the way.
“We have served more than 800 MedTech clients in more than 70 countries
by delivering an extensive suite of products, services and domain
expertise for this space and for our customers’ needs,” said Bhavik
Patel, senior vice president, IQVIA MedTech. “From helping our clients
develop and execute clinical trials to entering new markets to managing
regulatory processes, IQVIA MedTech supports a company’s individual
With access to cutting-edge technology and deep domain expertise, IQVIA
MedTech breaks down silos across the product lifecycle and provides
information at a geographic scale to drive expansion into global
markets. Using innovative technology and tailored-consulting services,
dedicated IQVIA MedTech account teams help companies address global
implications of client compliance programs and develop strategies to
keep pace within constantly evolving environments.
IQVIA MedTech’s comprehensive suite of Clinical to Commercial solutions
including Integrated Global Compliance involving Regulatory Intelligence
(RID), Regulatory Information Management (RIM) and Enterprise Quality
Management (QMS) and Commercial Compliance provide for comprehensive
regulatory and compliance needs. Additionally, MedTech products, managed
services, and consulting offerings can help companies automate and
address vigilance and safety processes. IQVIA MedTech offers a unique
single-source alternative to disparate providers, yet integrates well
with existing systems and processes.
For more information about IQVIA MedTech, visit https://www.iqvia.com.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics,
technology solutions and contract research services to the life sciences
industry. Formed through the merger of IMS Health and Quintiles, IQVIA
applies human data science — leveraging the analytic rigor and clarity
of data science to the ever-expanding scope of human science — to enable
companies to reimagine and develop new approaches to clinical
development and commercialization, speed innovation and accelerate
improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA
delivers unique and actionable insights at the intersection of
large-scale analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 58,000
employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The
company uses a wide variety of privacy-enhancing technologies and
safeguards to protect individual privacy while generating and analyzing
information on a scale that helps healthcare stakeholders identify
disease patterns and correlate with the precise treatment path and
therapy needed for better outcomes. IQVIA’s insights and execution
capabilities help biotech, medical device and pharmaceutical companies,
medical researchers, government agencies, payers and other healthcare
stakeholders tap into a deeper understanding of diseases, human
behaviors and scientific advances, in an effort to advance their path
toward cures. To learn more, visit www.iqvia.com.